Meta‐Analysis: Efficacy and Safety of Sequestrants for Bile Acid Diarrhoea
Alimentary Pharmacology & Therapeutics · 2025-12 · 62 (11-12) · 1054-1065
DOI: 10.1111/apt.70390 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 15.10.2025. Verfasst von Saam Dilmaghani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Bile Acids and Salts, Diarrhea, Irritable Bowel Syndrome, Sequestering Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
Bile acid diarrhoea, a common cause of diarrhoea‐predominant irritable bowel syndrome, has a similar prevalence to coeliac disease and inflammatory bowel diseases. The mainstay of treatment is bile acid sequestrants (BAS). The effectiveness of using bile acid‐targeted therapies remains unclear.
Aim
To compare BAS with placebo for bile acid diarrhoea.
Methods
We conducted a systematic review and meta‐analysis of randomised controlled trials comparing BAS to placebo using a comprehensive search of databases from inception to 8/1/2023. Inclusion required unequivocal diagnosis using serum or faecal biochemical parameters, or 75 SeHCAT. Co‐primary endpoints were ≥ 30% improvement in bowel movement consistency and frequency averaged over 7 days. Adverse effects were also summarised.
Results
Database search resulted in 1152 citations; 1 additional study was added. Ultimately, 6 trials (5 parallel arm, 1 crossover) involving 182 participants evaluated the effectiveness of BAS over 1–8 weeks. Participants were between the third and seventh decades of life and mostly female. The risk of bias was low except in one parallel and one crossover trial. Meta‐analysis of parallel‐design trials of sequestrants only showed a clinically significant reduction in stool consistency and frequency with pooled relative risks of 1.50 (95% CI: 1.14–1.96) and 2.80 (95% CI: 1.68–4.67), respectively. There was no observable heterogeneity ( I 2 = 0%), and the certainty of evidence was moderate. There was no statistically significant difference in adverse effects.
Conclusions
This study quantifies the significant and rapid improvement in both stool consistency and frequency with BAS in patients with objective diagnosis of bile acid diarrhoea. Sequestrants also appear well tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Library Services, Mayo Clinic, Rochester, Minnesota, USA.
- Evidence-Based Practice Center, Kern Center for the Science of Healthcare Delivery, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Michael Camilleri
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Dilmaghani, S., BouSaba, J., Lupianez-Merly, C., Prokop, L., Murad, M. H., & Camilleri, M. (2025). Meta‐Analysis: Efficacy and Safety of Sequestrants for Bile Acid Diarrhoea. Alimentary Pharmacology & Therapeutics, 62(11-12), 1054-1065. https://doi.org/10.1111/apt.70390
Vancouver
Dilmaghani S, BouSaba J, Lupianez-Merly C, Prokop L, Murad MH, Camilleri M. Meta‐Analysis: Efficacy and Safety of Sequestrants for Bile Acid Diarrhoea. Alimentary Pharmacology & Therapeutics. 2025;62(11-12):1054-1065. doi:10.1111/apt.70390
BibTeX
@article{Dilmaghani2025,
author = {Dilmaghani, Saam and BouSaba, Joelle and Lupianez-Merly, Camille and Prokop, Larry and Murad, M Hassan and Camilleri, Michael},
title = {Meta‐Analysis: Efficacy and Safety of Sequestrants for Bile Acid Diarrhoea},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
volume = {62},
number = {11-12},
pages = {1054--1065},
doi = {10.1111/apt.70390}
}
EUVIMED